Using aptamers to elucidate esophageal cancer clinical samples

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Zhenxu ^a   Lu, Yi ^a   Pu, Ying ^a   Liu, Jun ^a   Liu, Bo ^a   Yu, Bo ^a   Chen, Ke ^a   Fu, Ting ^b,d   Yang, Chaoyong James ^c,d   Liu, Huixia ^a   Tan, Weihong ^b,d  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN UNIVERSITY   (China)

^c XIAMEN UNIVERSITY   (China)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPCAM PROTEIN, HUMAN; EPITHELIAL CELL ADHESION MOLECULE; TUMOR MARKER;

ADENOCARCINOMA; BIOSYNTHESIS; CANCER STAGING; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; PATHOLOGY; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; EPITHELIAL CELL ADHESION MOLECULE; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; SELEX APTAMER TECHNIQUE;

EID: 84952017572     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18516     Document Type: Article

References (27)

1. Pennathur, A., Gibson, M. K., Jobe, B. A., Luketich, J. D. Oesophageal carcinoma. Lancet 381, 400-412 (2013).
2. Aggarwal, B. B., Danda, D., Gupta, S., Gehlot, P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol 78, 1083-1094 (2009).
3. Stoecklein, N. H. et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 6, 165-172 (2006).
4. Munz, M., Baeuerle, P. A., Gires, O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer. Res. 69, 5627-5629 (2009).
5. Fartoux, L., Decaens, T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 35, 21-30 (2011).
6. Schnell, U., Cirulli, V., Giepmans, B. N. EpCAM: structure and function in health and disease. Biochim. Biophys. Acta. 1828, 1989-2001 (2013).
7. Matsuda, T. et al. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma. Ann. Surg. Oncol. 21, 356-364 (2014).
8. Fong, D. et al. Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas. J. Clin. pathol. 67, 408-414 (2014).
9. Spizzo, G. et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J. Clin. Pathol. 64, 415-420 (2011).
10. Driemel, C. et al. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Oncogene 33, 4904-4915 (2014).
11. Kimura, H. et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int. J. Oncol. 30, 171-179 (2007).
12. Went, P., Dirnhofer, S., Schopf, D., Moch, H., Spizzo, G. Expression and prognostic significance of EpCAM. J. Cancer. Mol. 3, 169-174 (2008).
13. Xiong, X. et al. DNA AptamerMediated Cell Targeting. Angew. Chem. Int. Ed. Engl. 52, 1472-1476 (2013).
14. Li, J. et al. Self-assembly of DNA Nanohydrogels with Controllable Size and Stimuli-responsive Property for Targeted Gene Therapy. J. Am. Chem. Soc. 137, 1412-1415 (2015).
15. Zhao, Z. et al. Activatable Fluorescence/MRI Bimodal Platform for Tumor Cell Imaging via MnO2 Nanosheet-Aptamer Nanoprobe. J. Am. Chem. Soc. 136, 11220-11223 (2014).
16. Liang, H. et al. Functional DNA-containing nanomaterials: cellular applications in biosensing, imaging, targeted therapy. Acc. Chem. Res. 47, 1891-1901 (2014).
17. Chen, T. et al. DNA micelle flares for intracellular mRNA imaging and gene therapy. Angew. Chem. Int. Ed. Engl. 125, 2066-2070 (2013).
18. Hao, H., Zhen, Y., Wang, Z., Chen, F., Xie, X. A novel therapeutic drug for colon cancer: EpCAM scFvtruncated protamine (tp) siRNA. Cell. Biol. Int. 37, 860-864 (2013).
19. Pu, Y. et al. Using DNA aptamer probe for immunostaining of cancer frozen tissues. Anal. Chem. 87, 1919-1924 (2015).
20. Blom, R. L. et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann. Surg. Oncol. 20, 2693-2698 (2013).
21. Jemal, A. et al. Global cancer statistics. A. Cancer. J. Clin. 61, 69-90 (2011).
22. Jogi, A., Vaapil, M., Johansson, M., Pahlman, S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups. J. Med. Sci. 117, 217-224 (2012).
23. Ralhan, R. et al. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 10, 331-342 (2010).
24. Schnell, U., Kuipers, J., Giepmans, B. N. EpCAM proteolysis: new fragments with distinct functions Biosci. Rep. 33, 321-332 (2013).
25. Song, Y. et al. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal. Chem. 85, 4141-4149 (2013).
26. Kunavisarut, T., Kak, I., MacMillan, C., Ralhan, R., Walfish, P. G. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma. BMC Cancer 12, 523-532 (2012).
27. Qiu, L. et al. A targeted, self-delivered, photocontrolled molecular beacon for mRNA detection in living cells. J. Am. Chem. Soc. 135, 12952-12955 (2013).